Skip to main content
Premium Trial:

Request an Annual Quote

Biodesix Raises $4M

NEW YORK (GenomeWeb News) – Molecular diagnostics company Biodesix said in a regulatory document that it has raised about $4 million in a private financing.

The company did not respond to requests for comment, but in its Form D filed with the US Securities and Exchange Commission on Tuesday, Biodesix said that the type of securities offered were options, warrants, or other rights to acquire another security; security to be acquired upon the exercise of an option, warrant, or other right to acquire security; and promissory notes that may be converted into Biodesix's equity securities.

It did not identify the investors or say how the financing will be used.

In April 2012, the Boulder, Colo.-based firm raised $8.8 million in a follow-on sale of its Series D preferred shares. It also raised $12 million in a Series D extension in August 2012.

Four months ago, Biodesix said Medicare would cover its VeriStrat proteomic lung cancer test.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.